Can Fite Biopharma Ltd banner
C

Can Fite Biopharma Ltd
TASE:CANF

Watchlist Manager
Can Fite Biopharma Ltd
TASE:CANF
Watchlist
Price: 556 ILS -2.61% Market Closed
Market Cap: ₪23.5m

Wall Street
Price Targets

CANF Price Targets Summary
Can Fite Biopharma Ltd

There are no price targets for CANF.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Can Fite Biopharma Ltd Competitors:
Price Targets
ESQ
Esquire Financial Holdings Inc
17% Upside
IBEX
Ibex Ltd
46% Upside
SHLS
Shoals Technologies Group Inc
84% Upside
FAST
Fastenal Co
1% Upside

Revenue
Forecast

2% / Year
Past Growth
3 101% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
2% / Year
Past Growth
3 101% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 13 years the compound annual growth rate for Can Fite Biopharma Ltd's revenue is 2%. The projected CAGR for the next 3 years is 3 101%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-74%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-74%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CANF's stock price target?
Not Available

CANF doesn't have any price targets made by Wall Street professionals.

What is Can Fite Biopharma Ltd's Revenue forecast?
Projected CAGR
3 101%

For the last 13 years the compound annual growth rate for Can Fite Biopharma Ltd's revenue is 2%. The projected CAGR for the next 3 years is 3 101%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett